Analyst Expectations for Pacific Biosciences's Future
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 6 indifferent. The average price target is $11.22, representing an upside from the current price of $7.2. This average is a 15.83% decrease from the previous average price target of $13.33.
November 06, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a lower average price target could impact Pacific Biosciences' stock price.
The mixed analyst ratings indicate uncertainty about the company's future performance. The lower average price target suggests that analysts have lowered their expectations for the stock, which could potentially lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100